Our previous work on plants has indicated significant antimalarial and antiviral activities. Of these plants, two recipes are proposed for evaluation for COVID-19. It is Cinchona, an antimalarial and a combination of 4 plants with antiviral, antimalarial, antitussive and anti-inflammatory properties. The phase II clinical trial, with three arms and at a rate of 77 patients per arm, received the approval of the National Committee for Ethics and Health Research. This is a non-inferiority test aimed at comparing the therapeutic impact in "add on" to Azithromycin, phytomedicines versus Hydroxychloroquine in asymptomatic COVID-19 patients. After 10 days of treatment, viral clearance and symptom progression will be assessed on days 3, 6 and 14. Clinical, paraclinical and laboratory tests will be performed throughout the 3-month trial. Ethical and deontological considerations will be applied
All consenting subjects who meet the inclusion criteria will benefit from an individual file
which will include data relating to general information, the complete clinical examination
and the paraclinical examination. They are distributed randomly into three parallel groups,
each arm having a different treatment modality. A balanced randomization by permutation block
of 5 will be applied using the "Randomizer for Clinical Trial" application developed by the
company Medsharing). Laboratory examinations are carried out according to the procedures and
method by laboratories accredited in Guinea for the diagnosis of COVID19. Data is encoded,
entered and processed using statistical software.
The comparison between the three cohorts will be made using either the Anova test for
continuous variables or the chi-square test for categorical variables. The rate of change
over time of virologic clearance, fever and other symptoms values as well as the differences
for these rates between treatment arms will be tested using mixed-effects modeling.
The biological samples will be stored at the biobank of the National Institute of Public
Health of Guinea.
Combination Product: Hydroxychloroquine/Azithromycine
Dual treatment with Hydroxychloroquine and Azythromycin
Combination Product: Quinquina-Stevia/Azythromycin
Dual treatment with Quinquina/Stevia (3/0,5) and Azythromycin
Other Name: CILE
Combination Product: 4Plants/Azythromycin
Dual treatment with 4 plant species drug and Azythromycin
Other Name: ACAR
Inclusion Criteria:
- Eligible patients are adults with COVID-19 confirmed by a positive PCR (Polymerase
Chain Reaction) test and without symptoms
Exclusion Criteria:
- any patient hypersensitive to hydroxychloroquine or under traditional herbal treatment
in the two weeks preceding inclusion,
- any patient with other acute or chronic illnesses such as heart failure, arterial
hypertension, renal failure, hepatocellular failure, tuberculosis or unable to take
the oral treatment;
- any patient for whom one of the treatments under study is contraindicated according to
the doctor's opinion.
- pregnant women,
- severe neurological manifestations
Support Centers of Donka, Kenien and Gbessia
Conakry, Guinea